1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)

Abstract

Comprehensive genomic profiling (CGP) in advanced solid tumors has led to implement precision medicine in clinical practice. However, genomic alterations (GAs) detected are still not routinely used for therapeutic decision in the majority of the tumor types. The ESMO ESCAT ranks the GAs based on their clinical actionability. Since 2018, our Molecular Tumor Board (MTB) stratified the GAs detected in tissue/liquid biopsy based on ESCAT to guide treatment selection. Based on ESCAT, we aimed to assess clinical actionability of GAs through our MTB.